Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX)

Historical Holders from Q4 2018 to Q3 2025

Symbol
CLDX on Nasdaq
Type / Class
Equity / Common Stock, par value $.001
Shares outstanding
65.8M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
70.7M
Holdings value
$1.83B
% of all portfolios
0.003%
Grand Portfolio weight change
0%
Number of holders
177
Number of buys
87
Number of sells
-83
Average Value change %
+0%
Average buys %
+0.001%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
WELLINGTON MANAGEMENT GROUP LLP 11.1% +40% $191M $55.9M 7.39M +41.3% Wellington Management Group LLP 31 Oct 2025
Kynam Capital Management, LP 9.79% +27% $136M $30.1M 6.5M +28.4% Kynam Capital Management, LP 31 Mar 2025
FMR LLC 7.3% $102M 4.86M FMR LLC 31 Dec 2024
BlackRock, Inc. 7.3% -12.5% $101M -$13.8M 4.82M -12.1% BlackRock, Inc. 31 Mar 2025
Point72 Asset Management, L.P. 6.7% $90.9M 4.46M Point72 Asset Management, L.P. 02 Jul 2025
Bellevue Group AG 5.4% $93.6M 3.62M Bellevue Group AG 18 Aug 2025
Commodore Capital LP 4.6% -8% $78.3M -$8.32M 3.03M -9.6% Commodore Capital LP 30 Sep 2025
PRICE T ROWE ASSOCIATES INC /MD/ 3.6% -36% $61.6M -$30.4M 2.38M -33% T. Rowe Price Associates, Inc. 30 Sep 2025
EVENTIDE ASSET MANAGEMENT, LLC 2% $30.5M 1.36M Eventide Asset Management, LLC 30 Jun 2025

Institutional Holders of Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 70.7M $1.83B -$41M $25.87 177
2025 Q2 72.7M $1.48B -$19M $20.35 178
2025 Q1 73.6M $1.34B -$25.5M $18.15 170
2024 Q4 73.7M $1.86B -$10.9M $25.27 172
2024 Q3 71.8M $2.44B +$62M $33.99 174
2024 Q2 69.6M $2.58B +$1.33M $37.01 181
2024 Q1 69.3M $2.91B +$363M $41.97 196
2023 Q4 61M $2.42B +$411M $39.66 162
2023 Q3 50.6M $1.39B +$5.53M $27.52 140
2023 Q2 50.2M $1.7B +$19.5M $33.93 148
2023 Q1 49.5M $1.78B +$24.1M $35.98 158
2022 Q4 48.7M $2.17B -$9.32M $44.57 163
2022 Q3 49.3M $1.39B +$32.3M $28.11 146
2022 Q2 48.2M $1.3B -$45.7M $26.96 146
2022 Q1 49.6M $1.69B +$106M $34.06 157
2021 Q4 46.3M $1.79B +$97.4M $38.64 170
2021 Q3 43.2M $2.33B +$430M $53.99 156
2021 Q2 35.6M $1.19B +$60.3M $33.44 127
2021 Q1 34.5M $709M -$40.3M $20.60 109
2020 Q4 36.8M $645M +$72.2M $17.52 120
2020 Q3 32.2M $477M +$67.8M $14.83 82
2020 Q2 27.8M $361M +$311M $13.00 63
2020 Q1 3.95M $6.56M +$7.23K $1.66 32
2019 Q4 3.9M $8.71M +$448K $2.23 34
2019 Q3 3.71M $7.9M +$465K $2.13 40
2019 Q2 3.47M $9.29M +$2.11M $2.68 39
2019 Q1 2.6M $12.8M +$12.3M $4.92 39
2018 Q4 100K $20K +$20K $0.20 1